NCT01825083

Brief Summary

Procedures performed under sedation have the same severity in regards to morbidity and mortality as procedures performed under general anesthesia1. The demand for anesthesia care outside the operating room has increased tremendously and it poses, according to a closed claim analysis, major risks to patients. Both closed claim analysis identified respiratory depression due to over sedation as the main risk to patients undergoing procedures under sedation. The major problem is that hypoventilation is only detected at very late stages in patients receiving supplemental oxygen. Besides the respiratory effects of hypoventilation, hypercapnia can also lead to hypertension, tachycardia, cardiac arrhythmias and seizures. The incidence of anesthetized patients with obstructive sleep apnea has increased substantially over the last years along with the current national obesity epidemic. These patients are at increased risk of hypoventilation when exposed to anesthetic drugs. The context of the massive increase in procedural sedation and the extremely high prevalence of obstructive sleep apnea poses major respiratory risks to patients and it may, in a near future, increase malpractice claims to anesthesiologists. The development of safer anesthesia regimen for sedation are, therefore, needed. The establishment of safer anesthetics regimen for sedation is in direct relationship with the anesthesia patient safety foundation priorities. It addresses peri-anesthetic safety problems for healthy patient's. It can also be broadly applicable and easily implemented into daily clinical care. Ketamine has an established effect on analgesia but the effects of ketamine on ventilation have not been clearly defined. The investigators have demonstrated that the transcutaneous carbon dioxide monitor is accurate in detecting hypoventilation in patients undergoing deep sedation. Animal data suggest that when added to propofol in a sedation regimen, ketamine decreased hypoventilation when compared to propofol alone. It is unknown if ketamine added to a commonly used sedative agent (propofol) and fentanyl can decrease the incidence and severity of hypoventilation in patients undergoing deep sedation. The investigators hypothesize that patients receiving ketamine, propofol and fentanyl will develop less intraoperative hypoventilation than patients receiving propofol and fentanyl. The investigators also hypothesize that this effect will be even greater in patients with obstructive sleep apnea than patients without obstructive sleep apnea. Significance: Respiratory depression due to over sedation was identified twice as the major factor responsible for claims related to anesthesia. The high prevalence of obstructive sleep apnea combined with more complex procedures done in outpatient settings can increase physical risks to patients and liability cases to anesthesiologists. The main goal of this project is to establish the effect of ketamine in preventing respiratory depression to patients undergoing procedures under deep sedation using propofol and fentanyl. If the investigators can confirm our hypothesis, our findings can be valuable not only to anesthesiologist but also to other specialties (emergency medicine, gastroenterologists, cardiologists, radiologists) that frequently performed procedural sedation. The research questions is; does the addition of ketamine prevent hypoventilation during deep sedation using propofol and fentanyl? The hypotheses of this study: Ketamine will prevent hypoventilation during deep sedation cases.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 31, 2013

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 5, 2013

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2014

Completed
Last Updated

May 8, 2014

Status Verified

May 1, 2014

First QC Date

January 31, 2013

Last Update Submit

May 7, 2014

Conditions

Keywords

HypercarbiaTOSCA monitorKetamineFentanylIntraoperative monitoring

Outcome Measures

Primary Outcomes (1)

  • The total percentage time patients hypoventilate during the case

    The total percentage time patients hypoventilate during the case

    Day 1

Study Arms (2)

Ketamine

ACTIVE COMPARATOR

Ketamine administered 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.

Drug: Ketamine

Placebo

PLACEBO COMPARATOR

Saline group will received the same volume in saline as the ketamine dose

Drug: Placebo

Interventions

Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.

Also known as: Ketamine adminstration
Ketamine

0.9 % normal saline group receives same volume as the ketamine dose

Also known as: 0.9 % normal saline group receives same volume as ketamine dose
Placebo

Eligibility Criteria

Age18 Years - 64 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • ASA I and II
  • Age 18-64
  • Females undergoing sedation procedures

You may not qualify if:

  • Pregnant subjects
  • Breastfeeding
  • Patients or surgeon request
  • Difficult airway
  • Drop Out:
  • Patient or surgeon request
  • Conversion to general anesthesia .Inability to obtain data from CO2 monitor.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prentice Womens Hospital

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

Hypercapnia

Interventions

Ketamine

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • Gildasio De Oliveira, MD,MS

    Northwestern University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prinipal Investigator

Study Record Dates

First Submitted

January 31, 2013

First Posted

April 5, 2013

Primary Completion

March 1, 2014

Study Completion

March 1, 2014

Last Updated

May 8, 2014

Record last verified: 2014-05

Locations